Back to search results

ACTIVATE: AI Tool for Cancer Clinical Trial Matching

This study is testing a new artificial intelligence (AI) tool called MatchMiner-AI to help doctors find suitable clinical trials for cancer patients. The tool will send email notifications to oncologists (cancer doctors) with a ranked list of potential clinical trial options when AI models suggest a patient's cancer is progressing. This is in addition to the standard way doctors currently use MatchMiner-AI. The study aims to see if this new approach helps more patients get into clinical trials. You could be considered for this study if you are an adult (18 years or older) with a cancer diagnosis receiving care at Dana-Farber Cancer Institute (DFCI). The main goal is to measure the proportion of clinical trials identified over 1.5 years. The current status of this study is unclear.

Study design
This study plans to include 70,000 participants. It is an interventional study, meaning it tests a specific intervention, in this case, the MatchMiner-AI Artificial Intelligence Tool.
What's involved
No direct patient recruitment will occur as part of this protocol; all data will be obtained retrospectively or prospectively from routine clinical documentation and electronic health records.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint will be measured at the end of the 1.5-year duration of the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07232043

ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs

Not Yet Recruiting
NAAges 18+Interventional
Dana-Farber Cancer Institute
~70,000 participants
Updated 2026-04-28 on ClinicalTrials.gov
What's tested:MatchMiner-AI Artificial Intelligence Tool

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion clinical trials
Measured over Assessment will occur at the end of the 1.5 year duration of the intervention.

Conditions

Cancer

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Massachusetts1

Study leadership

  • Kenneth L Kehl, MD · PRINCIPAL_INVESTIGATOR · Dana-Farber Cancer Institute

Who to contact

Kenneth L Kehl, MD
[email protected]
617-632-4550
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

3.1 The potentially eligible patient population includes any adult (≥18 years old) with a cancer diagnosis receiving care at DFCI. No direct patient recruitment will occur as part of this protocol; all data will be obtained retrospectively or prospectively from routine clinical documentation and electronic health records. TrialForecast will involve aggregate queries of this dataset for cohort size estimation. The randomized interventional component (TrialMatch) is a health system level email "nudge" to treating oncologists providing a list of clinical trial options for patients who have progressive disease based on their imaging reports as detected using our previously developed, validated, and deployed AI model for that purpose. 23-25 Secondary outcomes in our study will include oncologist satisfaction with information delivered via these pipelines. All DFCI oncologists at any DFCI-owned/operated site (Longwood, Chestnut Hill, and regional campus sites) will be eligible to use our pipeline and may receive notifications about clinical trial options for their patients. In 2024, there were approximately 593 such oncologists who had outpatient appointments with at least one patient. Clinicians will constitute study participants as well, since they will have the opportunity to provide feedback on our pipeline to be analyzed by the study team.
3.2 Our project will focus on adults with cancer treated at DFCI, as above. We will not have any mechanism for identifying, targeting, or excluding pregnant women or prisoners.

Exclusion

3.2 Our project will focus on adults with cancer treated at DFCI, as above. We will not have any mechanism for identifying, targeting, or excluding pregnant women or prisoners.

What this trial measures

  • Proportion clinical trialsAssessment will occur at the end of the 1.5 year duration of the intervention.

    The effect of TrialMatch notifications is defined as the proportion of new systemic therapy starts which are clinical trials.